Device Trial Radar · NCT07179328
Focused Ultrasound Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoing Standard Chemotherapy
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Jun 4, 2025
Primary completion
Jul 2027
Study completion Nov 2027
Sponsor
- Lead sponsor
- Sunnybrook Health Sciences CentreAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety and feasibility of focused ultrasound (FUS)-mediated blood-brain barrier (BBB) disruption using the Next Generation Dome Helmet (NGDH) in adults with glioblastoma (GBM) undergoing the maintenance phase of the standard "Stupp protocol". Participants will: * Undergo repeated FUS BBB disruption treatments during the maintenance phase of temozolomide (TMZ) chemotherapy. * Receive intravenous ultrasound contrast (DEFINITY®) prior to each FUS session to facilitate targeted BBB disruption. * Undergo serial MRI scans and clinical assessments to evaluate safety and the extent of BBB opening. * Provide blood samples (and tumor tissue if available) for biomarker analysis related to BBB permeability, tumor presence, and treatment response. * Be followed for progression-free survival (PFS) and overall survival (OS) during routine neuro-oncology visits until end of life.
Conditions
- GBM
- Glioblastoma Multiforme (GBM)
- Glioblastoma Multiforme of Brain
- Glioblastoma Multiforme Glioma
- HGG
- Glioma
- Brain Tumor Adult
- Brain Tumor, Primary
Interventions
Focused Ultrasound Next Generation Dome HelmetDevice
The Next Generation Dome Helmet (FUS NG) is a non-invasive, MRI-guided focused ultrasound system developed at Sunnybrook Research Institute. It is used to disrupt the blood-brain barrier (BBB) in patients with glioblastoma during the maintenance phase of temozolomide (TMZ) therapy. The device allows targeted BBB opening using a fixed transducer array and intravenous DEFINITY® contrast.
Definity® Vial for (Perflutren Lipid Microsphere) Injectable SuspensionDrug
DEFINITY® Perflutren Injectable Microbubbles is an ultrasound contrast imaging agent that will be used for blood brain barrier opening during focused ultrasound. These microbubbles will be injected during the focused ultrasound procedure.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of Focused Ultrasound-Mediated BBB DisruptionTime frame: Participants will be evaluated at baseline, every 8 weeks during the first year, and every 12 weeks during the second year.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.